Polymyositis and dermatomyositis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| (10 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Effective measures for the secondary prevention of [ | Effective measures for the secondary prevention of polymyositis and dermatomyositis include regular follow ups, [[Cancer|malignancy]] screening, [[Lung|pulmonary]] protection, [[lifestyle]] modification, and prevention of [[medication]]-induced complications. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
*Effective measures for the secondary prevention of polymyositis and dermatomyositis include: | *Effective measures for the secondary prevention of polymyositis and dermatomyositis include:<ref name="AggarwalRider2017">{{cite journal|last1=Aggarwal|first1=Rohit|last2=Rider|first2=Lisa G.|last3=Ruperto|first3=Nicolino|last4=Bayat|first4=Nastaran|last5=Erman|first5=Brian|last6=Feldman|first6=Brian M.|last7=Oddis|first7=Chester V.|last8=Amato|first8=Anthony A.|last9=Chinoy|first9=Hector|last10=Cooper|first10=Robert G.|last11=Dastmalchi|first11=Maryam|last12=Fiorentino|first12=David|last13=Isenberg|first13=David|last14=Katz|first14=James D.|last15=Mammen|first15=Andrew|last16=de Visser|first16=Marianne|last17=Ytterberg|first17=Steven R.|last18=Lundberg|first18=Ingrid E.|last19=Chung|first19=Lorinda|last20=Danko|first20=Katalin|last21=García-De la Torre|first21=Ignacio|last22=Song|first22=Yeong Wook|last23=Villa|first23=Luca|last24=Rinaldi|first24=Mariangela|last25=Rockette|first25=Howard|last26=Lachenbruch|first26=Peter A.|last27=Miller|first27=Frederick W.|last28=Vencovsky|first28=Jiri|title=2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu|journal=Arthritis & Rheumatology|volume=69|issue=5|year=2017|pages=898–910|issn=23265191|doi=10.1002/art.40064}}</ref><ref name="KhanChristopher-Stine2011">{{cite journal|last1=Khan|first1=Sabiha|last2=Christopher-Stine|first2=Lisa|title=Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features|journal=Rheumatic Disease Clinics of North America|volume=37|issue=2|year=2011|pages=143–158|issn=0889857X|doi=10.1016/j.rdc.2011.01.001}}</ref><ref name="DoblougGaren2015">{{cite journal|last1=Dobloug|first1=Cecilie|last2=Garen|first2=Torhild|last3=Bitter|first3=Helle|last4=Stjärne|first4=Johan|last5=Stenseth|first5=Guri|last6=Grøvle|first6=Lars|last7=Sem|first7=Marthe|last8=Gran|first8=Jan Tore|last9=Molberg|first9=Øyvind|title=Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort|journal=Annals of the Rheumatic Diseases|volume=74|issue=8|year=2015|pages=1551–1556|issn=0003-4967|doi=10.1136/annrheumdis-2013-205127}}</ref><ref name="ChinoyFertig2007">{{cite journal|last1=Chinoy|first1=H.|last2=Fertig|first2=N.|last3=Oddis|first3=C. V|last4=Ollier|first4=W. E R|last5=Cooper|first5=R. G|title=The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis|journal=Annals of the Rheumatic Diseases|volume=66|issue=10|year=2007|pages=1345–1349|issn=0003-4967|doi=10.1136/ard.2006.068502}}</ref><ref name="DalakasHohlfeld2003">{{cite journal|last1=Dalakas|first1=Marinos C|last2=Hohlfeld|first2=Reinhard|title=Polymyositis and dermatomyositis|journal=The Lancet|volume=362|issue=9388|year=2003|pages=971–982|issn=01406736|doi=10.1016/S0140-6736(03)14368-1}}</ref><ref name="DouglasTazelaar2001">{{cite journal|last1=Douglas|first1=William W.|last2=Tazelaar|first2=Henry D.|last3=Hartman|first3=Thomas E.|last4=Hartman|first4=Robert P.|last5=Decker|first5=Paul A.|last6=Schroeder|first6=Darrell R.|last7=Ryu|first7=Jay H.|title=Polymyositis–Dermatomyositis-associated Interstitial Lung Disease|journal=American Journal of Respiratory and Critical Care Medicine|volume=164|issue=7|year=2001|pages=1182–1185|issn=1073-449X|doi=10.1164/ajrccm.164.7.2103110}}</ref> | ||
** | ** Regular follow ups | ||
*** Chest CT scan | ** [[Cancer|Malignancy]] screening include: | ||
*** Abdomen CT scan | *** Initially and annually diagnostic studies for three years such as:<ref name="TiniakouMammen2015">{{cite journal|last1=Tiniakou|first1=Eleni|last2=Mammen|first2=Andrew L.|title=Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review|journal=Clinical Reviews in Allergy & Immunology|volume=52|issue=1|year=2015|pages=20–33|issn=1080-0549|doi=10.1007/s12016-015-8511-x}}</ref> | ||
*** Pelvic CT scan | **** Chest [[Computed tomography|CT scan]] | ||
**** Abdomen [[Computed tomography|CT scan]] | |||
**** Pelvic [[Computed tomography|CT scan]] | |||
**** Gynecologic examination and [[Pelvis|pelvic]]/[[Gynecologic ultrasonography|transvaginal ultrasonogram]] | |||
* [[Lung|Pulmonary]] protection | |||
* Lifestyle modification including: | |||
** [[Physical therapy]] and [[Physical exercise|exercise]] | |||
**Healthy and well-balanced [[Diet (nutrition)|diet]] | |||
**[[Weight]] control | |||
**[[Sun exposure]] protection including: | |||
***Limiting time outdoors | |||
***Using [[sunscreen]] | |||
*Prevention of [[medication]]-induced complications | |||
** Screening for [[Osteoporosis|osteopenia]] and [[osteoporosis]] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 15:28, 18 April 2018
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis secondary prevention |
|
FDA on Polymyositis and dermatomyositis secondary prevention |
|
CDC on Polymyositis and dermatomyositis secondary prevention |
|
Polymyositis and dermatomyositis secondary prevention in the news |
|
Blogs on Polymyositis and dermatomyositis secondary prevention |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Effective measures for the secondary prevention of polymyositis and dermatomyositis include regular follow ups, malignancy screening, pulmonary protection, lifestyle modification, and prevention of medication-induced complications.
Secondary Prevention
- Effective measures for the secondary prevention of polymyositis and dermatomyositis include:[1][2][3][4][5][6]
- Regular follow ups
- Malignancy screening include:
- Pulmonary protection
- Lifestyle modification including:
- Physical therapy and exercise
- Healthy and well-balanced diet
- Weight control
- Sun exposure protection including:
- Limiting time outdoors
- Using sunscreen
- Prevention of medication-induced complications
- Screening for osteopenia and osteoporosis
References
- ↑ Aggarwal, Rohit; Rider, Lisa G.; Ruperto, Nicolino; Bayat, Nastaran; Erman, Brian; Feldman, Brian M.; Oddis, Chester V.; Amato, Anthony A.; Chinoy, Hector; Cooper, Robert G.; Dastmalchi, Maryam; Fiorentino, David; Isenberg, David; Katz, James D.; Mammen, Andrew; de Visser, Marianne; Ytterberg, Steven R.; Lundberg, Ingrid E.; Chung, Lorinda; Danko, Katalin; García-De la Torre, Ignacio; Song, Yeong Wook; Villa, Luca; Rinaldi, Mariangela; Rockette, Howard; Lachenbruch, Peter A.; Miller, Frederick W.; Vencovsky, Jiri (2017). "2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu". Arthritis & Rheumatology. 69 (5): 898–910. doi:10.1002/art.40064. ISSN 2326-5191.
- ↑ Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
- ↑ Dobloug, Cecilie; Garen, Torhild; Bitter, Helle; Stjärne, Johan; Stenseth, Guri; Grøvle, Lars; Sem, Marthe; Gran, Jan Tore; Molberg, Øyvind (2015). "Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort". Annals of the Rheumatic Diseases. 74 (8): 1551–1556. doi:10.1136/annrheumdis-2013-205127. ISSN 0003-4967.
- ↑ Chinoy, H.; Fertig, N.; Oddis, C. V; Ollier, W. E R; Cooper, R. G (2007). "The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis". Annals of the Rheumatic Diseases. 66 (10): 1345–1349. doi:10.1136/ard.2006.068502. ISSN 0003-4967.
- ↑ Dalakas, Marinos C; Hohlfeld, Reinhard (2003). "Polymyositis and dermatomyositis". The Lancet. 362 (9388): 971–982. doi:10.1016/S0140-6736(03)14368-1. ISSN 0140-6736.
- ↑ Douglas, William W.; Tazelaar, Henry D.; Hartman, Thomas E.; Hartman, Robert P.; Decker, Paul A.; Schroeder, Darrell R.; Ryu, Jay H. (2001). "Polymyositis–Dermatomyositis-associated Interstitial Lung Disease". American Journal of Respiratory and Critical Care Medicine. 164 (7): 1182–1185. doi:10.1164/ajrccm.164.7.2103110. ISSN 1073-449X.
- ↑ Tiniakou, Eleni; Mammen, Andrew L. (2015). "Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review". Clinical Reviews in Allergy & Immunology. 52 (1): 20–33. doi:10.1007/s12016-015-8511-x. ISSN 1080-0549.